Effects of IGF-I treatment on osteopenia in rats with advanced liver cirrhosis.

IGF-I is an anabolic hormone which has been reported to increase bone formation in several conditions of undernutrition. Advanced liver cirrhosis is associated with osteopenia and also with low serum levels of IGF-I. Previous results showed that low doses of IGF-I increase osteoblastic activity and decrease bone reabsorption in early liver cirrhosis. The aim of this study was to evaluate whether IGF-I-treatment also induces beneficial effect on osteopenia associated with advanced cirrhosis. Rats with ascitic cirrhosis were divided into two groups: group CI (n=10) which received saline and group CI+IGF (n=10) which were treated with IGF-I (2 microg/100 g bw x day, sc, during 21 days). Healthy controls which received saline were studied in parallel (CO n=10). On the 22nd day, the animals were sacrificed, and bone parameters were analyzed in femur. Posterior-anterior diameter was similar in all groups. No significant differences were observed in bone content of calcium, total proteins, collagen and hydroxyapatite in cirrhotic rats as compared with controls. However, CI rats showed significant reductions in total bone density (-13.5%, p<0.001) assessed by densitometry and radiological study. In CI+IGF rat bone density (assessed by densitometry) improved significantly as compared with CI animals. In summary, osteopenia characterized by loss of bone mass and preserved bone composition was found in rats with advanced cirrhosis induced by CCl4 and phenobarbital in drinking water. This bone disorder is partially restored by treatment with low doses of IGF-I during only three weeks. Thus, IGF-I could be considered as a possible therapy for osteopenia associated with advanced liver cirrhosis.

Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment.

BACKGROUND/AIMS: Liver cirrhosis is associated with osteopenia and also with low levels of IGF-I. This hormone has been reported to stimulate bone formation in states of undernutrition and low bone turnover. Our aims were to evaluate whether osteopenia develops in male Wistar rats with CCl4-induced cirrhosis and whether IGF-I is effective in the restoration of bone mass in these animals. METHODS: Cirrhotic rats were distributed into two groups: group CI (n = 12) which received placebo and group CI + IGF (n = 12) which was treated with human recombinant IGF-I (2 microg/100 g bw/day, s.c., 21 days). Twelve normal animals which received placebo constituted the control group. On the 22nd day, the animals were sacrificed, and bone parameters were analyzed in femur and/or tibia. RESULTS: Posterior-anterior and latero-medial diameters were similar in all groups. Also, no significant differences were observed in bone contents of calcium, total proteins, collagen and hydroxyapatite in CI rats as compared with controls. However, CI rats showed significant reductions in bone weight (-13.5%, p < 0.001), total bone density (-9.28%, p < 0.001), and increased perimedullar bone resorption and urinary levels of deoxypyridinoline (a marker of bone resorption). In CI + IGF rats these parameters improved significantly as compared with CI animals. CONCLUSIONS: Osteopenia characterized by loss of bone mass and preserved bone composition is found in rats with CCl4-induced cirrhosis. This bone disorder is partially corrected by treatment with low doses of IGF-I. Since osteoporosis seems to be the predominant form of osteopenia in patients with cirrhosis, IGF-I should be considered as a possible therapy for this disorder.

A potential experimental model for the study of osteopenia in CCl4 liver cirrhotic rats.

In order to search for an experimental model to further investigate the osteopenia associated to liver cirrhosis (LC), this study has been focused on investigating the occurrence of bone disorders in male rats to which LC histologically confirmed was induced through the validated procedure of CCl4 inhalation. Length, anteroposterior and lateromedial diameters, densitometry, mechanical stress resistance, hydroxyproline (OHprol) and calcium and phosphate contents were measured in femurs from control (n = 10) and liver cirrhosis rats (n = 10). It has been found that femurs from liver cirrhosis rats showed a significant reduction (p < 0.01) in bone weight (0.254 +/- 0.003 vs 0.230 +/- 0.004 g/100 g b.w.), anteroposterior (4.08 +/- 0.06 vs 3.69 +/- 0.05 mm) and lateromedial (5.33 +/- 0.05 vs 5.08 +/- 0.04 mm, p < 0.05) diameters, resistance to mechanical stress (405.8 +/- 9.5 vs 332.5 +/- 9.1 N) and total densitometry (0.416 +/- 0.005 vs 0.381 +/- 0.004 g/cm2). However, no significant differences were observed in bone length, calcium, OHprol and phosphate (all expressed as mg/100 mg fresh bone tissue) contents. Therefore, the proteins matrix to mineral contents ratio was not altered. These results indicate that in this model of experimental liver cirrhosis there is osteopenia characterized by bone frailty and reduced thickness, and it could offer an experimental model to study bone changes associated to liver cirrhosis.

HLA alleles in isolated populations from North Spain: origin of the Basques and the ancient Iberians.

HLA-A, -B, -DRB1, -DQA1 and -DQB1 alleles have been studied in three relatively isolated populations of northern Spain from Cantabria ( Pas Valleys inhabitants or Pasiegos and Cabuernigos) and from the Basque Country (Arratia Valley inhabitants). These populations have been compared with neighbouring ones and other Mediterraneans by using neighbour-joining dendrograms and plane genetic distances.